Hanall Biopharma, Completed the Clinical Trial Phase 1 of \'HL036\', New Medicine for Dry Eye Disease

Hanall Biopharma (CEO Kim Seong-uk and CEO Park Seung-guk) has clarified that CEO Park Seung-guk (photo) has received the commendation by the Minister of Health and Welfare at the 69 th  General Assembly of Korea Pharmaceutical Manufacturers Association for his contribution to the development of pharmaceutical industry in Korea. Senior Research Engineer Kim Yeong-ju of the Bio Research Center of Hanall Biopharma also has received the commendation by the chairman of Health and Welfare Committee under the National Assembly.  Seung-kook Park has been in the R&D field of biomedicine for over 20 years. As a leader of biomedicine in Korea, he has successfully developed \'Easyef Topical Solution\' of Daewoong Pharmaceutical, the first new medicine in bioengineering, during his service as a chief director of research center at Daewoong Pharmaceutical. After his relocation as a chief director of Bio Research Center of Hanall Biopharma in 2007, Park has lead the R&D field of antibody medicines and future Bio Better of Hanall. From 2013, he has been in charge of R&D and production of Hanall Biopharma as a CEO. ​   By using the commercialization technology of Bio Better, Hanall is developing bio medicines, and it is planning to apply for the clinical trial phase 1 of “protein medicine for dry eye disease” in Korea. Moreover, Hanall is developing the \'antibody with novel mechanism to cure severe autoimmune disease\', and it is expecting to achieve the global license within this year. ​       Seung-kook Park, a CEO of Hanall Biopharma (right) is taking the commendation by the Minister of Health and Welfare.

The release as fetched from its publisher. hanall.com ↗